Semnur Pharmaceuticals, Inc. (SMNR)

OTCMKTS · Delayed Price · Currency is USD
5.00
0.00 (0.00%)
At close: Apr 21, 2026
-57.95%
Market Cap 1.15B
Revenue (ttm) n/a
Net Income (ttm) -160.42M
Shares Out 230.21M
EPS (ttm) -0.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 148
Average Volume 259
Open 5.00
Previous Close n/a
Day's Range 5.00 - 5.00
52-Week Range 4.50 - 23.00
Beta 0.18
RSI 33.88
Earnings Date May 5, 2026

About Semnur Pharmaceuticals

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company. [Read more]

Industry Pharmaceutical Preparations
Founded 2013
Employees 10
Stock Exchange OTCMKTS
Ticker Symbol SMNR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.